{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_14304", "batch_size": 36, "batch_pos": 33, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 2, "answer": "no", "rationale": "The segment reports securing vaccines, handled by Q5.", "method": "llm_batch", "batch_id": "batch_2_18688", "batch_size": 188, "batch_pos": 185, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 3, "answer": "uncertain", "rationale": "LLM call failed.", "method": "llm_batch", "batch_id": "batch_3_19060", "batch_size": 100, "batch_pos": 97, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 4, "answer": "no", "rationale": "The segment is a statement, not a question.", "method": "llm_batch", "batch_id": "batch_4_1932", "batch_size": 94, "batch_pos": 91, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 5, "answer": "no", "rationale": "The segment reports facts without explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_14712", "batch_size": 88, "batch_pos": 85, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 6, "answer": "no", "rationale": "Segment does not contain a minimiser word combined with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_18448", "batch_size": 30, "batch_pos": 27, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 7, "answer": "no", "rationale": "Segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_6448", "batch_size": 200, "batch_pos": 200, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 8, "answer": "yes", "rationale": "Describes the details of a deal/acquisition (preparedness): 'secures up to 665,000 doses... includes an option for a further 40 million vaccines'.", "method": "llm_batch", "batch_id": "batch_8_17596", "batch_size": 161, "batch_pos": 158, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
